Thales to Offer Prime Factors' Bank Card Security System

Prime Factors and Thales Extend Collaboration to Help Customers Build More Secure Payment Applications Faster with BCSS and the Thales payShield HSM

Coffee

Apr 17, 2025

Complete Genomics Names Four Winners of Spatial Xcellerator Grant Program

SAN JOSE,Calif.,April 15,2025-- CompleteGenomics,a leading innovator in genomic sequencing,today announced four winners from 30 applicants to its Spatial Xcellerator Grant Program. Winning projects ad

Coffee

Apr 17, 2025

The Malaysia Gifts Fair 2025 Celebrates Its 15th Anniversary

Shaping the Future of Sustainable & Innovative Gifting KUALA LUMPUR,Malaysia,April 15,2025-- The Malaysia Gifts Fair 2025 is set to commemorate a significant milestone as it celebrates its 15th An

Coffee

Apr 17, 2025

XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials

SUZHOU,China,April 15,2025-- In January 2025 (U.S. time),the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted by XellSmart Biopharma

Coffee

Apr 17, 2025

The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months

SHANGHAI,April 16,2025-- The Lancet Child & Adolescent Health,a leading international journal in pediatric and adolescent medicine,has published the Phase III clinical trial results of ziresovir,

Coffee

Apr 17, 2025

Indonesia in Focus as FancyTech's B+ Funding Drives Global AI Content Growth

JAKARTA,Indonesia,April 16,2025-- FancyTech,the Grand Winner of the 2024 LVMH Innovation Award and an AI startup specializing in commercial content generation,has successfully closed its Series B+ fun

Coffee

Apr 17, 2025

Coffee

Thales to Offer Prime Factors&#039; Bank Card Security System

Complete Genomics Names Four Winners of Spatial Xcellerator Grant Program

The Malaysia Gifts Fair 2025 Celebrates Its 15th Anniversary

XellSmart&#039;s Allogeneic iPSC-derived Cell Therapies for Parkinson&#039;s Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials

The Lancet Child &amp; Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months

Indonesia in Focus as FancyTech&#039;s B+ Funding Drives Global AI Content Growth

Thales to Offer Prime Factors' Bank Card Security System

XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials

The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months

Indonesia in Focus as FancyTech's B+ Funding Drives Global AI Content Growth